Modeling and Simulation Archives

Fact Sheet

Non-Animal Navigator™: 专家策略与 AI 生物模拟减少、优化或替代动物实验

Certara Non-Animal Navigator™ 解决方案通过以下方式助力企业转型：

Danielle Pillsbury2025 年 4 月 30 日

Announcement

Certara 举办 Second Annual Certainty U.S. 活动

Certara’s premier client conference explores how in-silico methods and biosimulation at scale derisk every stage…

Danielle Pillsbury2025 年 4 月 22 日

Webinar

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

2025 年 6 月 17 日 - 美国东部时间上午 11:00

Danielle Pillsbury2025 年 4 月 21 日

Blog

In case you missed it: CHI + Certara Webinar on Artificial Intelligence (AI) -Powered Model-Informed Drug Development (MIDD)

2025 年 4 月 18 日 What’s next for drug development? Recapping our MIDD in the age of…

Danielle Pillsbury2025 年 4 月 18 日

Press Release

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal…

Simona Colucci2025 年 4 月 14 日

Publication

HIV 病毒学抑制青少年中长效注射用 cabotegravir 与长效注射用 rilpivirine 联合用药的安全性研究（IMPAACT 2017/MOCHA）：一项 1/2 期、多中心、开放标签、非比较性的剂量探索研究

The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…

Danielle Pillsbury2025 年 3 月 20 日

Publication

MIDD in Japan – Implementations, challenges and opportunities

In Japan, there has been a growing adoption of Model Informed Drug Development (MIDD) approaches…

Danielle Pillsbury2025 年 3 月 12 日

On-Demand Webinar

人工智能时代的模型引导的药物开发

Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…

Danielle Pillsbury2025 年 3 月 10 日

Publication

Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach

This study explores a model-based meta-analysis (MBMA) and a clinical utility index (CUI) approach to…

Danielle Pillsbury2025 年 3 月 4 日

Blog

药物开发中 PK/PD 建模的机器学习

Pharmacometricians can use machine learning for PK/PD modeling to help them characterize the safety and…

Danielle Pillsbury2025 年 3 月 4 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

建模与模拟

Non-Animal Navigator™: 专家策略与 AI 生物模拟减少、优化或替代动物实验

Certara 举办 Second Annual Certainty U.S. 活动

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

In case you missed it: CHI + Certara Webinar on Artificial Intelligence (AI) -Powered Model-Informed Drug Development (MIDD)

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

HIV 病毒学抑制青少年中长效注射用 cabotegravir 与长效注射用 rilpivirine 联合用药的安全性研究（IMPAACT 2017/MOCHA）：一项 1/2 期、多中心、开放标签、非比较性的剂量探索研究

MIDD in Japan – Implementations, challenges and opportunities

人工智能时代的模型引导的药物开发

Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach

药物开发中 PK/PD 建模的机器学习

订阅时事通讯

快捷链接

解决方案

联系我们